Scarica l'app Stockscreener
0.21
1.87%
-0.004
Viracta Therapeutics Inc Borsa (VIRX) Ultime notizie
Viracta Therapeutics' SWOT analysis: stock focus narrows amid pipeline shift - Investing.com
Viracta Therapeutics, Inc. (NASDAQ:VIRX) Short Interest Update - Defense World
Viracta Therapeutics Inc (NASDAQ: VIRX) Has Great Upside Potential - Stocks Register
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook By Investing.com - Investing.com Australia
Epstein-Barr Virus (EBV) Market A Deep Dive into Current - openPR
Viracta Therapeutics' SWOT analysis: focused strategy reshapes stock outlook - Investing.com
Viracta Therapeutics faces Nasdaq delisting over non-compliance By Investing.com - Investing.com Australia
Viracta Therapeutics faces Nasdaq delisting over non-compliance - Investing.com
Viracta Therapeutics faces Nasdaq delisting risk - Investing.com India
Viracta Therapeutics faces Nasdaq delisting risk By Investing.com - Investing.com Canada
Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World
VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK
Viracta Therapeutics Highlights Strategic Focus and Financials - TipRanks
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Sunesis: Q3 Earnings Snapshot - mySA
Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech
Viracta Cuts Workforce 42%, Narrows Focus on PTCL Drug as Cash Runway Tightens - StockTitan
Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR
Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter
VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK
Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times
Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com
Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada
Viracta Therapeutics Announces Reprioritization of - GlobeNewswire
Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan
Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance
T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic
Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR
Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic
Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa
Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India
Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech
Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter
The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle
Viracta Therapeutics Inc (VIRX) Stock: Navigating a Year of Volatility - The InvestChronicle
Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire
Are Smart Investors Making the Right Decision? Viracta Therapeutics Inc (VIRX) - SETE News
Ratio Review: Analyzing Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
What is the investor’s view on Viracta Therapeutics Inc (VIRX)? - US Post News
Viracta Therapeutics Inc (VIRX) can make a big difference with a little luck - SETE News
Viracta Therapeutics Inc (VIRX)’s stock decline to 0.22 per share - US Post News
Ratio Analysis: Unpacking Viracta Therapeutics Inc (VIRX)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
Viracta Therapeutics stock hits 52-week low at $0.27 - Investing.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):